​

C4 Therapeutics (CCCC) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

CCCC Stock Forecast

C4 Therapeutics (CCCC) stock forecast, based on 14 Wall Street analysts, predicts a 12-month average price target of $7.00, with a high of $10.00 and a low of $5.00. This represents a 238.16% increase from the last price of $2.07.

$2 $3 $4 $5 $6 $7 $8 $9 $10 $11 High: $10 Avg: $7 Low: $5 Last Closed Price: $2.07

CCCC Stock Rating

C4 Therapeutics stock's rating consensus is Buy, based on 14 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 10 Buy (71.43%), 3 Hold (21.43%), 1 Sell (7.14%), and 0 Strong Sell (0.00%).

Buy
Total 14 0 1 3 10 Strong Sell Sell Hold Buy Strong Buy

CCCC Price Target Upside V Benchmarks

TypeNameUpside
StockC4 Therapeutics238.16%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts-15
Avg Price Target-$5.00$7.80
Last Closing Price$2.07$2.07$2.07
Upside/Downside-141.55%276.81%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jan, 2617---8
Dec, 2516---7
Nov, 2516---7
Oct, 25161--8
Sep, 25-42--6
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Dec 17, 2025Barclays$5.00$2.26121.24%141.55%
Sep 23, 2025Derek ArchilaWells Fargo$10.00$2.80257.14%383.09%
Sep 22, 2025Etzer DaroutBarclays$10.00$3.16216.46%383.09%
Sep 16, 2025Barclays$8.00$3.41134.60%286.47%
Sep 15, 2025Sudan LoganathanStephens$6.00$3.5768.07%189.86%
Dec 19, 2024Derek ArchilaWells Fargo$12.00$4.31178.42%479.71%
Sep 19, 2024Etzer DaroutBMO Capital$20.00$6.87191.12%866.18%
Jan 03, 2023Wells Fargo$9.00$6.3142.63%334.78%
Apr 28, 2022Credit Suisse$10.00$8.8512.99%383.09%
Apr 11, 2022Chi FongBank of America Securities$15.00$8.0187.27%624.64%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Dec 02, 2025Cowen & Co.Buyinitialise
Sep 23, 2025Wells FargoOverweightOverweighthold
Sep 22, 2025BarclaysOverweightOverweighthold
Sep 16, 2025BarclaysOverweightinitialise
Sep 15, 2025StephensOverweightupgrade
Sep 03, 2025GuggenheimBuyinitialise
Dec 19, 2024Wells FargoEqual-WeightOverweightupgrade
Sep 19, 2024BMO CapitalOutperformOutperformhold
Dec 13, 2023Piper SandlerBuyupgrade
Feb 24, 2023Credit SuisseUnderperformNeutralupgrade

Financial Forecast

EPS Forecast

$-3 $-2 $-1 $0 $1 $2 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28 Dec 29
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28Dec 29
Reported$-1.87$-2.59$-2.67------
Avg Forecast$-2.05$-2.59$-2.60$-1.49$-1.41$-1.22$-1.20$-0.94$1.41
High Forecast$-2.05$-2.59$-2.33$-1.41$-1.35$-0.89$-0.62$-0.83$1.55
Low Forecast$-2.05$-2.59$-2.86$-1.58$-1.45$-1.55$-1.65$-1.03$1.24
Surprise %-8.78%-2.69%------

Revenue Forecast

$0 $300M $600M $900M $1B $2B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28 Dec 29
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28Dec 29
Reported$45.78M$31.10M$20.76M------
Avg Forecast$33.08M$39.80M$21.45M$35.79M$30.39M$21.62M$21.62M$118.30M$1.23B
High Forecast$33.08M$39.80M$28.59M$40.79M$32.72M$23.28M$21.62M$127.38M$1.32B
Low Forecast$33.08M$39.80M$17.13M$30.29M$27.66M$19.68M$21.62M$107.69M$1.12B
Surprise %38.40%-21.86%-3.25%------

Net Income Forecast

$-200M $-130M $-60M $10M $80M $150M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28 Dec 29
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28Dec 29
Reported$-86.04M$-126.50M$-132.49M------
Avg Forecast$-100.64M$-117.73M$-132.49M$-74.23M$-97.23M$-84.61M$-78.75M$-64.93M$97.53M
High Forecast$-80.51M$-94.18M$-105.99M$-70.10M$-93.98M$-61.73M$-43.19M$-57.36M$107.26M
Low Forecast$-120.76M$-141.28M$-158.99M$-78.37M$-100.48M$-107.50M$-114.32M$-71.41M$86.16M
Surprise %-14.51%7.45%-------

CCCC Forecast FAQ

Is C4 Therapeutics stock a buy?

C4 Therapeutics stock has a consensus rating of Buy, based on 14 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 10 Buy, 3 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that C4 Therapeutics is a favorable investment for most analysts.

What is C4 Therapeutics's price target?

C4 Therapeutics's price target, set by 14 Wall Street analysts, averages $7 over the next 12 months. The price target range spans from $5 at the low end to $10 at the high end, suggesting a potential 238.16% change from the previous closing price of $2.07.

How does C4 Therapeutics stock forecast compare to its benchmarks?

C4 Therapeutics's stock forecast shows a 238.16% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for C4 Therapeutics over the past three months?

  • January 2026: 12.50% Strong Buy, 87.50% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • December 2025: 14.29% Strong Buy, 85.71% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • November 2025: 14.29% Strong Buy, 85.71% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is C4 Therapeutics’s EPS forecast?

C4 Therapeutics's average annual EPS forecast for its fiscal year ending in December 2024 is $-1.49, marking a -44.19% decrease from the reported $-2.67 in 2023. Estimates for the following years are $-1.41 in 2025, $-1.22 in 2026, $-1.2 in 2027, $-0.94 in 2028, and $1.41 in 2029.

What is C4 Therapeutics’s revenue forecast?

C4 Therapeutics's average annual revenue forecast for its fiscal year ending in December 2024 is $35.79M, reflecting a 72.43% increase from the reported $20.76M in 2023. The forecast for 2025 is $30.39M, followed by $21.62M for 2026, $21.62M for 2027, $118.3M for 2028, and $1.23B for 2029.

What is C4 Therapeutics’s net income forecast?

C4 Therapeutics's net income forecast for the fiscal year ending in December 2024 stands at $-74.235M, representing a -43.97% decrease from the reported $-132M in 2023. Projections indicate $-97.23M in 2025, $-84.614M in 2026, $-78.754M in 2027, $-64.93M in 2028, and $97.53M in 2029.